ICG-EG8-Sulfo-OSu

Call for price

– Increase hydrophilic characteristics by PEGylation
– Monoclonal antibody-ICG conjugates functions as an autoquencher
– Suitable wavelength for in vivo imaging (ex. 774nm/em. 805nm)

Related Products:
ICG-EG4-Sulfo-OSu, ICG-Sulfo-OSu

Chemical Name: 2-[7-[1,1-Dimethyl-3-(4-sulfobutyl)-2H-benzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethyl-3-hexanoylamino-[3,6,9,12,15,18,21,24-octaoxa-26-(3-sulfosuccinimidyl)oxyhexacosanoyl]-1H-benzo[e]indolium, sodium salt

Appearance: Green to dark green powder or solid
Purity: ≥80% (HPLC)
MW: 1353.57, C68H89N4NaO19S2

Storage Condition: -20°C
Shipping Condition: with blue ice

Clear
DescriptionDataReferencesS.D.S

Product Description
ICG is a fluorophore, and it has been utilized for over a half-century in human clinical use. Conventional activated ICG dye, ICG-Sulfo-OSu has been utilized in in vivo imaging research as antibody conjugates. However, due to the hydrophobic characteristics which unspecific bound to antibodies are seen (results in higher background). As a next generation of ICG dye, ICG with short PEG linkers such as ICG-PEG4-Sulfo-OSu and ICG-PEG8-SUlfo-OSu are synthesized to increase the hydrophilicity character of the dye. The PEGylated ICGs shows higher covalent binding to antibodies, significantly reducing unspecific binding. Therefore, ICG with short PEG linkers is found to be more suitable compound for in vivo imaging research.


Structural Formula


Advantage of PEGylated ICG
PEGylated ICG is more suitable for in vivo imaging due to low background.

PEGylated ICG Derivatives (ICG-EGn-Sulfo-OSu)

Non-PEGylated ICG (ICG-Sulfo-Osu)

<Conjugation Ability>


<In vivo Background>


<Performance of PEGylated ICG>

<ICG-EG4, EG8 Sulfo-OSu>
1.Sano, K.; Nakajima, T.; Miyazaki, K.; Ohuchi, Y.; Ikegami, T.; Choyke, L. P.; Kobayashi, H.; Bioconjugate Chem., 24, 811-816, (2013).

<ICG-Sulfo-OSu>
1. Ogawa, M.; Kosaka, N.; Choyke, L. P.; Kobayashi, H.; Cancer Res., 69, 1268 – 1272 (2009).
2. Kosaka, N.; Ogawa, M.; Sato, N., Choyke, L.; P.; Kobayashi, H.; J Invest Dermatol, 129, 2818 E822 (2009).
3. Kosaka N.; Ogawa, M.; Choyke, P. L.; Kobayashi H.; Future Oncol., 5, 1501-11 (2009).
4. Nakajima T,; Mitsunaga M,; Bander NH,; Heston WD,; Choyke PL,; Kobayashi H.; Bioconjug Chem., 22,1700-1705 (2011).
5. Ogawa, M.; Regino, C. A.; Seidel, J.; Green, M. V.; Xi, W.; Williams, M.; Kosaka, N.; Choyke, P. L.; Kobayashi, H.; Bioconjug Chem., 20, 2177-84 (2009).

COVID-19 Announcement

Due to rising concerns regarding the COVID-19 (Coronavirus 2019) outbreak, Dojindo Molecular Technologies, Inc will be taking the necessary steps to prioritize public health and safety.

Scroll to Top